darbepoetin alfa (NuPIAO) / 3SBio - LARVOL DELTA

Canakinumab with darbepoetin in patients with lower-risk MDS who are ESA-refractory (YouTube) - "Jeffrey Lancet...discusses findings from a Phase I trial (NCT04798339) evaluating the combination of interleukin 1β (IL-1β) neutralizing antibody canakinumab with darbepoetin in the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) who are refractory to erythropoietin stimulating agents (ESA). The combination inhibited inflammasome activation, hypothesized as a key driver of MDS pathogenesis, although this did not translate to clinical responses."

Interview • Video

3SBio: Annual Report 2015 (3SBio) - Anticipated launch for anemia associated with CKD in 2020

Anticipated launch • Biosimilar

3SBio: Interim Results 2016 Investor Conference Call (3SBio) - Anticipated initiation of P2 trial in anemia associated with CKD in early 2017

Anticipated new P2 trial • Biosimilar